Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands

Journal of Medicinal Chemistry

Volumn 49, Issue 23, 2006, Pages 6858-6868

  Habtemariam, Abraha ^a   Melchart, Michael ^a   Fernández, Rafael ^a   Parsons, Simon ^a   Oswald, Iain D H ^a   Parkin, Andrew ^a   Fabbiani, Francesca P A ^a   Davidson, James E ^a   Dawson, Alice ^a   Aird, Rhona E ^a   Jodrell, Duncan I ^a   Sadler, Peter J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIKETONE; CISPLATIN; DOXORUBICIN; ETHYLENEDIAMINE; PHENYLENEDIAMINE; POLYCYCLIC AROMATIC HYDROCARBON; RUTHENIUM COMPLEX;

ARTICLE; COLON CANCER; CROSS RESISTANCE; DRUG STRUCTURE; DRUG SYNTHESIS; GEOMETRY; HUMAN; HUMAN CELL; LUNG CANCER; OVARY CANCER; PANCREAS CANCER; STRUCTURE ACTIVITY RELATION;

2,2'-DIPYRIDYL; ANTINEOPLASTIC AGENTS; BENZENE DERIVATIVES; CARBOPLATIN; CELL LINE, TUMOR; CHELATING AGENTS; CISPLATIN; CRYSTALLOGRAPHY, X-RAY; DIAMINES; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIGANDS; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; POLYCYCLIC COMPOUNDS; RUTHENIUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750969384     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060596m     Document Type: Article

References (68)

1. Clarke, M. J.; Zhu, F.; Frasca, D. R. Non-platinum chemotherapeutic metallopharmaceuticals. Chem. Rev. 1999, 99, 2511-2533.
2. Allardyce, C. S.; Dyson, P. J. Ruthenium in medicine: Current clinical uses and future prospects. Platinum Met. Rev. 2001, 45, 62-69.
3. Clarke, M. J. Oncological implication of the chemistry of ruthenium. Met. Ions Biol. Syst. 1980, 11, 231-83.
4. Clarke, M. J.; Bitler, S.; Rennert, D.; Buchbinder, M.; Kelman, A. D. Reduction and subsequent binding of ruthenium ions catalyzed by subcellular components. J. Inorg. Biochem. 1980, 12, 79-87.
5. Velders, A. H.; Kooijman, H.; Spek, A. L.; Haasnoot, J. G.; De Vos, D.; Reedijk, J. Strong differences in the in vitro cytotoxicity of three isomeric dichlorobis(2-phenylazopyridine)ruthenium(II) complexes. Inorg. Chem. 2000, 39, 2966-2967.
6. Hotze, A. C. G.; Bacac, M.; Velders, A. H.; Jansen, B. A. J.; Kooijman, H.; Spek, A. L.; Haasnoot, J. G.; Reedijk, J. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes. J. Med. Chem. 2003, 46, 1743-1750.
7. 2O. Inorg. Chim. Acta 1994, 224, 15-18.
8. Rademaker-Lakhai, J. M.; Van Den Bongard, D.; Pluim, D.; Beijnen, J. H.; Schellens, J. H. M. A phase I and pharmacological study with imidazolium-trans-DMSO-irnidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin. Cancer Res. 2004, 10, 3717-3727.
9. Alessio, E. Synthesis and reactivity of Ru-, Os-, Rh-, and Ir-halidesulfoxide complexes. Chem. Rev. 2004, 104, 4203-4242.
10. Sava, G.; Gagliardi, R.; Bergamo, A.; Alessio, E.; Mestroni, G. Treatment of metastases of solid mouse tumors by NAMI-A: Comparison with cisplatin. cyclophosphamide and dacarbazine. Anticancer Res. 1999, 19, 969-972.
11. Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Ruthenium anticancer drugs. Met, Ions Biol. Syst. 2004, 42, 323-351.
12. Peti, W.; Pieper, T.; Sommer, M.; Keppler, B. K.; Giester, G. Synthesis of tumor-inhibiting complex salts containing the anion trans- tetrachlorobis(indazole)ruthenate(III) and crystal structure of the tetraphenylphosphonium salt. Eur. J. Inorg. Chem. 1999, 1551-1555.
13. Yan, Y. K.; Melchart, M.; Habtemariam, A.; Sadler, P. J. Organometallic chemistry, biology and medicine: Ruthenium arene anticancer complexes. Chem. Commun. 2005, 4764-4776.
14. Melchart, M.; Sadler, P. J. Ruthenium arene anticancer complexes. In Bioorganometallics: Biomolecules, Labeling, Medicine; Jaouen, G., Ed.; Wiley-VCH Verlag: Weinheim, 2006; pp 39-64.
15. Morris, R. E.; Aird, R. E.; Murdoch, P. d. S.; Chen, H.; Cummings, J.; Hughes, N. D.; Parsons, S.; Parkin, A.; Boyd, G.; Jodrell, D. I.; Sadler, P. J. Inhibition of cancer cell growth by ruthenium(II) arene complexes. J. Med. Chem. 2001, 44, 3616-3621.
16. Aird, R. E.; Cummings, J.; Ritchie, A. A.; Muir, M.; Morris, R. E.; Chen, H.; Sadler, P. J.; Jodrell, D. I. In vitro and in vivo activity and cross resistance profiles of novel ruthenium(II) organometallic arene complexes in human ovarian cancer. Br. J. Cancer 2002, 86, 1652-1657.
17. Wang, F.; Chen, H.; Parsons, S.; Oswald, I. D. H.; Davidson, J. E.; Sadler, P. J. Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts. Chem.-Eur. J. 2003, 9, 5810-5820.
18. Wang, F.; Habtemariam, A.; van der Geer Erwin, P. L.; Fernandez, R.; Melchart, M.; Deeth, R. J.; Aird, R.; Guichard, S.; Fabbiani, F. P. A.; Lozano-Casal, P.; Oswald, I. D. H.; Jodrell, D. I.; Parsons, S.; Sadler, P. J. Controlling ligand substitution reactions of organometallic complexes: Tuning cancer cell cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 18269-18274.
19. Novakova, O.; Chen, H.; Vrana, O.; Rodger, A.; Sadler, P. J.; Brabec, V. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media. Biochemistry 2003, 42, 11544-11554.
20. Chen, H.; Parkinson, J. A.; Parsons, S.; Coxall, R. A.; Gould, R. O.; Sadler, P. J. Organometallic ruthenium(II) diamine anticancer complexes: Arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts. J. Am. Chem. Soc. 2002, 124, 3064-3082.
21. Liu, H.; Wang, F.; Parkinson, J. A.; Bella, J.; Sadler, P. J. Ruthenation of duplex and single-stranded d(CGGCCG) by organometallic anticancer complexes. Chem.-Eur. J. 2006, 12, 6151-6165.
22. Chen, H.; Parkinson, J. A.; Novakova, O.; Bella, J.; Wang, F.; Dawson, A.; Gould, R.; Parsons, S.; Brabec, V.; Sadler, P. J. Induced-fit recognition of DNA by organometallic complexes with dynamic stereogenic centers. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 14623-14628.
23. Chen, H.; Parkinson, J. A.; Morris, R. E.; Sadler, P. J. Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: Novel recognition mechanisms. J. Am. Chem. Soc. 2003, 125, 173-186.
24. Fernandez, R.; Melchart, M.; Habtemariam, A.; Parsons, S.; Sadler, P. J. Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes. Chem.-Eur. J. 2004, 10, 5173-5179.
25. 2(pta)] (pta = 1,3,5-triaza-7- phosphatricyclo[3.3.1.1]decane): A water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells. Chem. Commun. 2001, 1396-1397.
26. Carso, F.; Rossi, M. Antitumor titanium compounds. Mini-Rev. Med. Chem. 2004, 4, 49-60.
27. Kopf-Maier, P.; Kopf, H. Tumor inhibition by titanocene complexes. Activity against B16 melanoma and colon 38 carcinoma. Arzneimittel-Forschung. 1987, 37, 532-534.
28. Kröger, N.; Kleeberg, U. R.; Mross, K.; Edler, L.; Sass, G.; Hossfeld, D. K. Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer. Onkologie 2000, 23, 60-62.
29. Guo, M.; Sun, H.; McArdle, H. J.; Gambling, L.; Sadler, P. J. Uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancer cells: Understanding the mechanism of action of the anticancer drug titanocene dichloride. Biochemistry 2000, 39, 10023-10033.
30. Fichtner, I.; Pampillon, C.; Sweeney, N. J.; Strohfeldt, K.; Tacke, M. Antitumor activity of Titanocene Y in xenografted Caki-1 tumors in mice. Anti-Cancer Drugs 2006, 17, 333-336.
31. Jaouen, G.; Top, S.; Vessières, A. Organometallics targeted to specific biological sites: Development of new therapies. In Bioorganometallics: Biomolecules, Labeling, Medicine; Jaouen, G., Ed.; Wiley-VCH Verlag: Weinheim, 2006; pp 65-95.
32. Zelonka, R. A.; Baird, M. C. Benzene complexes of ruthenium(II). Can. J. Chem. 1972, 50, 3063-3072.
33. Bennett, M. A.; Smith, A. K. Arene ruthenium(II) complexes formed by dehydrogenation of cyclohexadiene with ruthenium(III) trichloride, J. Chem. Soc., Dalton Trans. 1974, 233-241.
34. Birch, A. J.; Rao, G. S. Reductions by metal-ammonia solutions and related reagents. Adv. Org. Chem. 1972, 8, 1-65.
35. Harvey, R. G. Metal-ammonia reduction of aromatic molecules. Synthesis 1970, 2, 161-172.
36. Rabideau, P. W. The metal-ammonia reduction of aromatic com-pounds. Tetrahedron 1989, 45, 1579-1603.
37. 6-Hexamethylbenzene)ruthenium complexes. Inorg. Synth. 1982, 21, 74-78.
38. 4-1, 5-cyclooctadiene)ruthenium(0): Efficient synthesis, chemistry, and catalytic properties. Organometallics 1991, 10, 3237-3245.
39. 6-naphthalene) ruthenium(0): A convenient route to new ruthenium(0) complexes. J. Chem. Soc., Dalton Trans. 1984, 2255-2257.
40. 4-cycloocta-1, 5-diene)ruthenium(0) complexes and their conversion into the corresponding arene-dichlororuthenium(II) complexes. J. Chem. Soc., Dalton Trans. 1982, 1019-1022.
41. 4-cycloocta-1,5-diene) complexes. J. Organomet. Chem. 1998, 551, 37-47.
42. 4- cycloocta-1,5-diene)ruthenium(0) complexes. J. Organomet. Chem. 2001, 621, 246-253.
43. 2. Organometallics 1995, 14, 4222-4227.
44. 6-[2n]cyclophane) ruthenium(II) compounds and related chemistry. J. Am. Chem. Soc. 1986, 108, 3324-3334.
45. 6- hexamethylbenzeneruthenium(II)-β-diketone complexes: Their reactions with mono- and bidentate neutral ligands. J. Organomet. Chem. 2005, 690, 1218-1225.
46. Brown, R.; Hirst, G. L.; Gallagher, W. M.; McIlwrath, A. J.; Margison, G. P.; van der Zee, A. G.; Anthoney, D. A. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997, 15, 45-52.
47. Plumb, J. A.; Strathdee, G.; Sludden, J.; Kaye, S. B.; Brown, R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine- induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000, 60, 6039-6044.
48. Ren, J.; Jenkins, T. C.; Chaires, J. B. Energetics of DNA intercalation reactions. Biochemistry 2000, 39, 8439-8447.
49. He, Q.; Ohndorf, U.-M.; Lippard, S. J. Intercalating residues determine the mode of HMG1 domains A and B binding to cisplatin-modified DNA. Biochemistry 2000, 39, 14426-14435.
50. Chen, Y.; Parkinson, J. A.; Guo, Z.; Brown, T.; Sadler, P. J. A new platinum anticancer drug forms a highly stereoselective adduct with duplex DNA. Angew. Chem., Int. Ed. 1999, 38, 2060-2063.
51. Reedijk, J. Improved understanding in platinum antitumor chemistry. Chem. Commun. 1996, 801-806.
52. Yu, E. W.; McDermott, G.; Zgurskaya, H. I.; Nikaido, H.; Koshland, D. E., Jr. Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump. Science 2003, 300, 976-980.
53. Wang, F.; Habtemariam, A.; Melchart, M.; Fernandez, R.; van der Geer Erwin, P. L.; Aird, R.; Jodrell, D., I.; Sadler, P. J. Unpublished results.
54. Scolaro, C.; Geldbach, T. J.; Rochat, S.; Dorcier, A.; Gossens, C.; Bergamo, A.; Cocchietto, M.; Tavernelli, I.; Sava, G.; Rothlisberger, U.; Dyson, P. J. Influence of hydrogen-bonding substituents on the cytotoxicity of RAPTA compounds. Organometallics 2006, 25, 756-765.
55. 6-arene-ruthenium(II) complexes of alanine and guanine derivatives. Inorg. Chim. Acta 1990, 168, 93-100.
56. Wang, F.; Xu, J.; Habtemariam, A.; Bella, J.; Sadler, P. J. Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: Detection of a sulfenato intermediate. J. Am. Chem. Soc. 2005, 127, 17734-17743.
57. Carmona, D.; Vega, C.; Lahoz, F. J.; Atencio, R.; Oro, L. A.; Lamata, M. P.; Viguri, F.; San Jose, E. Synthesis and stereochemistry of half-sandwich alkynyl amino acidate complexes of rhodium(III), iridium(III), and ruthenium(II). Organometallics 2000, 19, 2273-2280.
58. Peacock, A. F. A.; Habtemariam, A.; Fernández, R.; Walland, V.; Fabbiani, F. P. A.; Parsons, S.; Aird, R. E.; Jodrell, D. I.; Sadler, P. J. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions. J. Am. Chem. Soc. 2006, 128, 1739-1748.
59. Wiederholt, K.; McLaughlin, L. W, A 2,2″-bipyridine ligand for incorporation into oligodeoxynucleotides: Synthesis, stability and fluorescence properties of ruthenium-DNA complexes. Nucleic Acids Research 1999, 27, 2487-2493.
60. Sheldrick, G. M., University of Göttingen, Germany, 2001-2004.
61. Blessing, R. H., An empirical correction for absorption anisotropy. Acta Crystallogr., Sect. A 1995, A51, 33-38.
62. Sheldrick, G. M., Programs for crystal structure analysis (Release 97-2); Institüt für Anorganische Chemie der Universität, Tammanstrasse 4, D-3400 Göttingen, Germany, 1998.
63. Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A. Completion and refinement of crystal structures with SIR92. J. Appl. Crystallogr. 1993, 26, 343-350.
64. Altomare, A.; Burla, M. C.; Camalli, M.; Cascarano, G. L.; Giacovazzo, C.; Guagliardi, A.; Moliterni, A. G. G.; Polidori, G.; Spagna, R., SIR97: A new tool for crystal structure determination and refinement. J. Appl. Crystallogr. 1999, 32, 115-119.
65. Beurskens, P. T.; Beurskens, G.; Bosnian, W. P.; de Gelder, R.; Garcia-Granda, S.; Gould, R. O.; Israel, R.; Smits, J. M. M. Crystallography Laboratory, University of Nijmegen, The Netherlands, 1996.
66. Betteridge, P. W.; Carruthers, J. R.; Cooper, R. I.; Prout, K.; Watkin, D. J., CRYSTALS version 12: Software for guided crystal structure analysis. J. Appl. Crystallogr 2003, 36, 1487.
67. Nardelli, M., Modeling hydroxyl and water H atoms. J. Appl. Crystallogr. 1999, 32, 563-571.
68. 6 ruthenium complexes. J. Organomet. Chem. 1977, 127, C55-C58.